OptimizeRx (NASDAQ:OPRX) Receives “Market Outperform” Rating from JMP Securities

OptimizeRx (NASDAQ:OPRX)‘s stock had its “market outperform” rating restated by investment analysts at JMP Securities in a research note issued to investors on Thursday,Benzinga reports. They currently have a $8.00 price target on the stock. JMP Securities’ target price would suggest a potential upside of 45.06% from the stock’s current price.

Other equities analysts have also recently issued research reports about the stock. Roth Mkm reissued a “buy” rating and issued a $16.00 target price (down previously from $20.00) on shares of OptimizeRx in a report on Thursday, November 14th. Barclays reduced their price objective on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, November 14th. William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. Stephens started coverage on OptimizeRx in a research note on Friday, December 20th. They issued an “equal weight” rating and a $5.50 target price on the stock. Finally, B. Riley cut their target price on OptimizeRx from $17.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, December 24th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $9.06.

OptimizeRx Stock Performance

Shares of NASDAQ:OPRX traded down $0.16 on Thursday, reaching $5.52. 25,330 shares of the company’s stock were exchanged, compared to its average volume of 153,033. The business’s 50-day moving average is $5.24 and its two-hundred day moving average is $6.59. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx has a fifty-two week low of $3.78 and a fifty-two week high of $16.65. The firm has a market capitalization of $101.59 million, a price-to-earnings ratio of -4.15 and a beta of 1.38.

Insiders Place Their Bets

In other news, CEO William J. Febbo bought 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the purchase, the chief executive officer now owns 601,253 shares of the company’s stock, valued at approximately $3,012,277.53. This trade represents a 3.44 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in OPRX. BNP Paribas Financial Markets boosted its holdings in shares of OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after buying an additional 2,414 shares during the period. Greenwood Capital Associates LLC boosted its holdings in shares of OptimizeRx by 8.0% during the third quarter. Greenwood Capital Associates LLC now owns 67,356 shares of the company’s stock worth $520,000 after acquiring an additional 4,999 shares during the period. SBI Securities Co. Ltd. acquired a new position in shares of OptimizeRx in the fourth quarter valued at approximately $25,000. Quest Partners LLC increased its position in OptimizeRx by 15,965.6% during the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after buying an additional 9,739 shares during the period. Finally, SG Americas Securities LLC bought a new stake in shares of OptimizeRx during the 4th quarter valued at $51,000. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.